Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Delia Goletti

Showing results (171-180 of 310) with videos related to

Pageof 31
Sort By:
Plos One|September 11, 2010
Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIV-infected persons?Delia Goletti, Alamelu Raja, Basirudeen Syed Ahamed Kabeer, et al.
Frontiers in Immunology|November 12, 2024
Immunomodulatory effects of cysteamine and its potential use as a host-directed therapy for tuberculosisSaeid Najafi-Fard, Chiara Farroni, Linda Petrone, et al.
International Journal of Environmental Research and Public Health|September 9, 2022
Latent Tuberculosis Infection in Haematopoietic Stem Cell Transplant Recipients: A Retrospective Italian Cohort Study in Tor Vergata University Hospital, RomeMirko Compagno, Assunta Navarra, Laura Campogiani, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 13, 2021
Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2Linda Petrone, Elisa Petruccioli, Valentina Vanini, et al.
International Journal of Molecular Sciences|January 21, 2023
Cysteamine/Cystamine Exert Anti-<i>Mycobacterium abscessus</i> Activity Alone or in Combination with AmikacinIvana Palucci, Alessandro Salustri, Flavio De Maio, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|February 28, 2024
Perspectives on development and advancement of new tuberculosis vaccinesChristopher da Costa, Christine S Benn, Thomas Nyirenda, et al.
Cells|January 11, 2022
Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 TherapyTonino Alonzi, Alessandra Aiello, Linda Petrone, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 8, 2024
Detection of Mycobacterium tuberculosis DNA in CD34<sup>+</sup> peripheral blood mononuclear cells of adults with tuberculosis infection and diseaseFederica Repele, Tonino Alonzi, Assunta Navarra, et al.
Neurology International|August 27, 2025
Characterization of QuantiFERON-TB-Plus Results in Patients with Tuberculosis Infection and Multiple SclerosisElisa Petruccioli, Luca Prosperini, Serena Ruggieri, et al.
The Journal of Infection|March 4, 2014
High urine IP-10 levels associate with chronic HCV infectionLinda Petrone, Teresa Chiacchio, Valentina Vanini, et al.
Pageof 31

Showing results (171-180 of 310) with videos related to

Sort By:
Pageof 31
Plos One|September 11, 2010
Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIV-infected persons?Delia Goletti, Alamelu Raja, Basirudeen Syed Ahamed Kabeer, et al.
Frontiers in Immunology|November 12, 2024
Immunomodulatory effects of cysteamine and its potential use as a host-directed therapy for tuberculosisSaeid Najafi-Fard, Chiara Farroni, Linda Petrone, et al.
International Journal of Environmental Research and Public Health|September 9, 2022
Latent Tuberculosis Infection in Haematopoietic Stem Cell Transplant Recipients: A Retrospective Italian Cohort Study in Tor Vergata University Hospital, RomeMirko Compagno, Assunta Navarra, Laura Campogiani, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 13, 2021
Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2Linda Petrone, Elisa Petruccioli, Valentina Vanini, et al.
International Journal of Molecular Sciences|January 21, 2023
Cysteamine/Cystamine Exert Anti-<i>Mycobacterium abscessus</i> Activity Alone or in Combination with AmikacinIvana Palucci, Alessandro Salustri, Flavio De Maio, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|February 28, 2024
Perspectives on development and advancement of new tuberculosis vaccinesChristopher da Costa, Christine S Benn, Thomas Nyirenda, et al.
Cells|January 11, 2022
Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 TherapyTonino Alonzi, Alessandra Aiello, Linda Petrone, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 8, 2024
Detection of Mycobacterium tuberculosis DNA in CD34<sup>+</sup> peripheral blood mononuclear cells of adults with tuberculosis infection and diseaseFederica Repele, Tonino Alonzi, Assunta Navarra, et al.
Neurology International|August 27, 2025
Characterization of QuantiFERON-TB-Plus Results in Patients with Tuberculosis Infection and Multiple SclerosisElisa Petruccioli, Luca Prosperini, Serena Ruggieri, et al.
The Journal of Infection|March 4, 2014
High urine IP-10 levels associate with chronic HCV infectionLinda Petrone, Teresa Chiacchio, Valentina Vanini, et al.
Pageof 31